<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877119</url>
  </required_header>
  <id_info>
    <org_study_id>14905</org_study_id>
    <nct_id>NCT04877119</nct_id>
  </id_info>
  <brief_title>sFlt-1:PlGF Ratio in Gestational Diabetes: PREDICTION (PREeclampsia in DIabetiC gestaTION) Study</brief_title>
  <acronym>PREDICTION</acronym>
  <official_title>Predictive Value for Preeclampsia of the sFlt-1:PlGF (Soluble Foms-like Tyrosine Kinase 1/Placental Growth Factor) Ratio in Pregnancy Complicated by Gestational Diabetes: The PREDICTION (PREeclampsia in DIabetiC gestaTION) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is&#xD;
      elevated in pregnant women before the clinical onset of preeclampsia and can be used to&#xD;
      predict the preeclampsia. However, its predictive value in pregnancy complicated by&#xD;
      gestational diabetes is unclear. This study purposes are to validate a ratio of serum sFlt-1&#xD;
      to PlGF that would be predictive of the absence or presence of preeclampsia in the short term&#xD;
      in women with singleton pregnancies complicated by diabetes in whom preeclampsia was&#xD;
      suspected, and to evaluate the relationship among sFlt-1 to PlGF and placental&#xD;
      histopathological alterations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, observational, prospective study designed to validate a cutoff point of the&#xD;
      sFlt-1:PlGF ratio for the prediction of the short-term absence or presence of preeclampsia in&#xD;
      pregnancy complicated by gestational diabetes (GDM).&#xD;
&#xD;
      GDM women will be recruited at diabetes screening time (16-18 or 24-27 gestational weeks),&#xD;
      performed according with the Italian National Guidelines by 75g - 2 hour Oral Glucose&#xD;
      Tolerance Test. GDM will be defined according with International Association of Diabetes and&#xD;
      Pregnancy Study Groups/World Health Organization 2013 criteria. A standardized medical&#xD;
      history will be obtained in all the women at the time of their first visit, collecting data&#xD;
      about maternal age, parity, last menstruation, pre-gestational weight, history of GDM,&#xD;
      hypertension and macrosomia in previous pregnancies, family history of diabetes mellitus,&#xD;
      education and employment. Moreover, during their visit, the women's weights were taken and&#xD;
      their blood pressure measured. Blood samples for assessments of sFlt-1:PlGF ratio will be&#xD;
      collected at visit 1 (baseline visit) and every 30±7 days after the previous visit until 36&#xD;
      gestational week (for a maximum of 4 determinations). At baseline and at each follow-up&#xD;
      visits update of medical history, clinical assessments, laboratory testing and pregnancy&#xD;
      evolution will be evaluated. During pregnancy all women will be receive standard diabetes and&#xD;
      obstetric care, according with national guidelines. Diagnostic criteria for preeclampsia will&#xD;
      be a new onset of both hypertension (systolic blood pressure ≥140 mmHg, diastolic blood&#xD;
      pressure ≥90 mmHg, or both) and proteinuria (2+ protein or greater on dipstick urinalysis,&#xD;
      ≥300 mg of protein per 24-hour urine collection, ≥30 mg /dl of protein in a spot urine&#xD;
      sample, or a ratio of protein to creatinine of ≥30 mg/mmol) after 20 weeks of gestation. Only&#xD;
      cases that met these prespecified criteria will be included in the analyses. At delivery,&#xD;
      data items on maternal body weight at the end of pregnancy, time and mode of delivery,&#xD;
      newborn bodyweight, preeclampsia as well as other maternal and fetal outcomes will be&#xD;
      collected. Placental histopathological alterations will be detected in women who delivery by&#xD;
      planned Cesarian section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>25 Weeks</target_duration>
  <primary_outcome>
    <measure>Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia</measure>
    <time_frame>25 weeks</time_frame>
    <description>Evaluation of a specific SFLT-1 / PLGF ratio cat-off point for women with diabetes during pregnancy (pre-pregnancy or gestational) in the prediction of preeclampsia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between SFLT-1 / PLGF ratio and placental histopathology</measure>
    <time_frame>25 weeks</time_frame>
    <description>Correlation between SFLT-1 / PLGF ratio and rate of placental histopathological alterations in pregnancy complicated by diabetes (pre-pregnancy or gestational)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Gestational Hypertension</condition>
  <condition>Pre-Eclampsia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with gestational diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of GDM in the current pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Twin pregnancies&#xD;
&#xD;
          -  Pre-pregnancy diabetes (type 1 or type 2 diabetes)&#xD;
&#xD;
          -  Gestosis already diagnosed during the current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina Bianchi, MD, PhD</last_name>
    <phone>+39050995136</phone>
    <email>c.bianchi@ao-pisa.toscana.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana - U.O. Malattie Metaboliche e Diabetologia</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Bianchi, MD, PhD</last_name>
      <phone>+39050995136</phone>
      <email>c.bianchi@ao-pisa.toscana.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Cristina Bianchi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

